# 1 Title

- 2 Criteria to Achieve Safe Antimicrobial Intravenous-to-Oral Switch in Hospitalised Adult Populations:
- 3 A Systematic Rapid Review
- 4 Author Information
- 5 Eleanor J Harvey<sup>1</sup>, Monsey McLeod<sup>2</sup>, Caroline De Brún<sup>3</sup>, Diane Ashiru-Oredope<sup>1,4</sup>\*

# 6 Affiliations

- 7 <sup>1</sup>Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use
- 8 (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA), London, UK
- 9 <sup>2</sup> Antimicrobial Prescribing and Medicines Optimisation, NHS England & NHS Improvement, London,
- 10 UK
- <sup>3</sup> Knowledge and Library Services, United Kingdom Health Security Agency (UKHSA), London, UK
- <sup>4</sup> School of Pharmacy, University of Nottingham, Nottingham, UK

# 13 Corresponding Author

14 \*Diane Ashiru-Oredope: diane.ashiru-oredope@ukhsa.gov.uk, +44 2083 276689

### 15 Abstract

- 16 Introduction: Antimicrobial stewardship and patient safety strategies include early intravenous-to-
- 17 oral switch (IVOS) for antimicrobials.
- 18 Aim: This rapid review aimed to assess and collate IVOS criteria from the literature to achieve safe
- and effective antimicrobial IVOS in the hospital inpatient adult population.
- 20 **Method:** The rapid review follows the PRISMA statement and is registered with PROSPERO.
- 21 Systematic literature searches were conducted. Articles of adult populations published between
- 22 2017-2021 were included. IVOS criteria from UK hospital IVOS policies were categorised to inform
- 23 the framework synthesis of the literature criteria.
- 24 **Results:** IVOS criteria from 45/164 (27%) UK IVOS policies were categorised into a 5-section
- 25 framework: 1-Timing of IV antimicrobial review, 2-Clinical signs and symptoms, 3-Infection markers,
- 26 4-Enteral route, and 5-Infection exclusions. The literature search identified 477 papers, of which 16
- 27 were included. The most common timing for review was 48-72 hours from initiation of intravenous
- antimicrobial (n=5, 30%). Nine studies (56%) stated clinical signs and symptoms must be improving.
- 29 Temperature was the most frequently mentioned infection marker (n=14, 88%). Endocarditis had
- 30 the highest mention as an infection exclusion (n=12, 75%). Overall, 33 IVOS criteria were identified
- 31 to go forward into the Delphi process.
- 32 Conclusion: Through the rapid review, 33 IVOS criteria were collated and presented within 5 distinct
- and comprehensive sections. The literature highlighted the possibility of reviewing IVOS before 48-
- 34 72 hours, and of presenting HR, BP and RR as a combination early warning score criterion. The
- 35 criteria identified can serve as a starting point of IVOS criteria review for any institution globally, as
- 36 no country or region limits were applied. Further research is required to achieve consensus on IVOS
- 37 criteria from healthcare professionals that manage patients with infections.

# 38 What is already known on this topic

- 39 Antimicrobial intravenous-to-oral switch has benefits such as decreased risk of catheter-related
- 40 infections, reduced equipment costs and increased patient mobility and comfort. Acute hospitals
- 41 often develop and implement individualised IVOS policies with varying levels of evidence base.

### 42 What this study adds

43 This study provides evidence-based IVOS criteria to standardise practice in hospital settings.

### How this study might affect research, practice or policy

- 45 IVOS criteria can be taken forward through a consensus process with healthcare professionals
- 46 providing the care for hospitalised adult patients and making the decisions regarding infection
- 47 management. In the acute hospital setting, IVOS criteria can be operationalised to promote best
- 48 practice. The criteria can also be considered as part of organisation-wide audits and quality/policy
- 49 incentives.

### 50 1 Introduction

51	Antimicrobial resistance (AMR) is a public health threat, <sup>1</sup> and tackling this threat requires joint
52	efforts at local, national and global levels across all care settings. <sup>2</sup> In the acute hospital care setting,
53	antibiotic consumption is known to promote resistant and multidrug-resistant bacteria leading to
54	healthcare-associated infections. <sup>3</sup> Antibiotic prescribing in England continued to rise in acute
55	hospitals between 2016 and 2020, with specialist hospitals accounting for the highest increase of
56	31.2%.4

57 Antimicrobial stewardship (AMS) is defined as a set of strategies to promote the responsible use of antimicrobials<sup>5</sup> for the purpose of protecting public health.<sup>6</sup> Across secondary care, the COVID-19 58 59 pandemic had a negative impact on AMS activities, but evidence suggests the pandemic also encouraged collaboration between infection specialists and non-specialists to strengthen activities 60 going forward.<sup>7</sup> Antimicrobial intravenous-to-oral switch (IVOS) has been classified as a "low-hanging 61 62 fruit" AMS activity; in other words, an attainable AMS strategy despite constrained limitations.<sup>8</sup> 63 The literature outlines numerous benefits for IVOS; including decreased risk of catheter-related infections, reduced equipment costs and increased patient mobility and comfort.<sup>9, 10</sup> Additionally, 64 decreased medical equipment usage has the potential to reduce hospital's carbon footprint.<sup>11</sup> In 65 66 clinically stable patients, studies report that a timely IVOS is safe and of equal efficacy to the full course of IV therapy,<sup>12</sup> with no negative reports on patient outcome.<sup>12</sup> In the United Kingdom (UK), 67 68 the national Start Smart – Then Focus AMS Toolkit recommends IVOS as an important outcome 69 following review of prescribed antimicrobial within 48-72 hours. 70 Acute hospitals have developed and implemented their own individualised local IVOS policies and 71 there is currently no standardised national criteria recommended for IVOS in the UK. The evidence-72 base behind the criteria included in the individualised policies is largely unknown. Additionally, they 73 include a variety of criteria themes and nuances in criterion wording. The standardisation of clinical

74 guidance, whether protocols, checklists or other, has led to enhanced patient safety and outcomes

75 and driven improved quality of care.<sup>13-15</sup>

- 76 This rapid review aims to evaluate the evidence-base for IVOS criteria and collate criteria into
- common themes. This review will subsequently inform a Delphi consensus-gathering process, led by
- 78 the UK Health Security Agency (UKHSA), to establish standardised, evidence-based, national
- 79 antimicrobial IVOS criteria. The UK has previously never had nation-wide IVOS criteria available for
- 80 use by hospitals, this review will form the basis for included IVOS criteria.

### 81 2 Method

- 82 2.1 Protocol and registration
- 83 This review was informed by the World Health Organisation<sup>16</sup> and Cochrane<sup>17</sup> rapid review protocols,
- and follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020
- item checklist (**Supplementary Table S1**) and guidance.<sup>18,19</sup> The review protocol is registered with
- 86 PROSPERO [registration number CRD42022320343].<sup>20</sup>

#### 87 2.2 Eligibility criteria

- 88 Articles were included in the review if they were written in English, pertained to an adult (18 years of
- age or over) population, were clinical trials, review articles, studies or point prevalence studies with
- a publication date between January 2017 and December 2021, related to the AMS strategy IVOS and
- 91 with specified IVOS criteria.
- 92 Studies were excluded if they were case reports and non-studies e.g., conference abstracts,
- 93 editorials, letters, notes, or related to one particular antimicrobial or specific infection (to exclude
- 94 non-generalisable criteria).

#### 95 2.3 Information sources

- 96 Literature search terms were devised alongside an experienced UKHSA Knowledge and Evidence
- 97 Specialist (CD). Systematic searches were conducted in OVID Embase and OVID Medline databases.
- 98 For the initial searches, no start date limit was set, and databases were searched up to 15 December
- 99 2021.

#### 100 2.4 Search strategy

- 101 The defined research question was: What are the criteria necessary to achieve a safe and effective
- antimicrobial intravenous-to-oral switch in the hospital inpatient adult population?
- 103 See **Table 1** for database search strategies.
- 104 2.5 Selection process
- 105 Article duplicates were removed on EndNote. One researcher (EH) screened all titles and abstracts
- 106 for articles relevant to the research question. From this initial screening, Akhloufi *et al.*'s paper
- 107 published in 2017 was identified as including an IVOS literature review,<sup>21</sup> thus 2017 onwards became
- 108 an inclusion criterion to capture evidence published since the most recently identified review. One
- 109 researcher (EH) screened full articles to ascertain focus of article and identify IVOS criteria. A second
- 110 researcher (DAO) reviewed the focus themes for accuracy.
- 111 A second assessment of a random 20% sample of articles dated between the years 2017 and 2021
- 112 was conducted by a third researcher (MM). Discrepancies were resolved between two reviewers
- 113 (EH, MM) with a third reviewed (DAO) as arbiter.
- 114 2.6 Data collection process
- 115 A data extraction Excel spreadsheet was designed with the following column headings: Authors, Year
- of publication, Title, Journal, Edition, Pages, Month, Article type, DOI, Keywords, Abstract, URL link,
- 117 Database, Platform, Language, Continent research conducted in, Country/area, Sample size,
- 118 Population, Focus, Specifics, Healthcare professional mention, Key findings, Exclude/Include, Reason,
- 119 Additional comments.
- 120 The Focus heading options included AMS (focus on AMS strategies such as IVOS), Antimicrobial
- 121 (focus on an individual or class of antimicrobial(s)) or Infection (focus on specific infection). Studies
- 122 with an AMS focus would further be classified under the Specifics column as General (non-IVOS AMS
- 123 strategy) or IV Switch (IVOS AMS strategy). The studies in the IV Switch column were further
- 124 evaluated to ascertain if they included IVOS switch criteria.

#### 125 2.7 Data items

- 126 The primary outcome sought from the literature was safety of antimicrobial IVOS, defined by
- 127 measurable IV switch criteria for adults (to include review time, clinical signs and symptoms,
- 128 infection markers, enteral route, infection exclusions).
- 129 Additional outcomes were reduced healthcare associated infections, reduced catheter-related
- 130 infections, reduced hospital length of stay, reduced costs (e.g., drug equipment), reduced staff
- 131 workload, reduced IV administration errors, increased patient comfort and mobility, improved AMS
- 132 practice.
- 133 2.8 Study risk of bias assessment
- 134 The included studies were not assessed for internal validity with a risk of bias tool. This differs to the
- 135 protocol registered on PROSPERO. This decision was agreed by all co-authors and the reasons are: 1)
- as a rapid review the risk of bias can be omitted,<sup>22</sup> and 2) risk of bias tools become more relevant for
- 137 studies assessing effectiveness of interventions, whereas this review aimed to identify IVOS criteria
- 138 to subsequently inform a Delphi consensus-gathering process.

#### 139 2.9 Synthesis methods

There was heterogeneity of study designs and outcome measures. This was expected and was not
investigated as outside scope of the rapid review. A framework synthesis on included studies was
completed.

- 143 2.9.1 Development of framework
- 144 The framework was derived based on an analysis of IVOS criteria obtained from a sample of UK
- acute hospital IVOS policies sought though stratified sampling. The target number of IVOS policies
- 146 was 41 (25%), to include polices from English Trusts and Scottish Health Boards and Northern Ireland
- 147 and Wales all-country policies. Hospitals from England were selected from an 'All England Trusts and
- 148 Trust Types' UKHSA datasheet by hospital type (acute small, acute medium, acute large, acute
- 149 multi-service, acute specialist, acute teaching) and region (East of England, London, Midlands,
- 150 North East and Yorkshire, North West, South East, South West) to ensure representative sampling.

- 151 English IVOS policies were obtained through internet search or MicroGuide application access. IVOS
- 152 policies from Scotland's Health Boards were obtained through internet search, and from Northern
- 153 Ireland and Wales through internet search and email correspondence. An Excel spreadsheet was
- designed to collate criteria under headings to inform framework sections.
- 155 2.10 Certainty of evidence
- 156 All included studies were peer-reviewed articles, enhancing the certainty of the evidence. Studies
- 157 were not formally graded. High evidence rating [H] was assigned to high quality evidence such as
- 158 clinical trials and reviews, and medium evidence rating [M] was assigned to lower quality studies
- such as prospective studies and point prevalence studies.

#### 160 3 Results

#### 161 3.1 Framework synthesis

162 Forty-two acute hospitals (28%, n=148) from England were selected for review of their IVOS policies,

163 two Health Boards (14%, n=14) from Scotland and the All-Wales policy from Wales. No IVOS policy

- 164 from Northern Ireland was identified at the time of the study period. Overall, 45 (27%, n=164) acute
- 165 hospital IVOS policies from three UK nations were included for review. IVOS criteria were collated on
- an Excel spreadsheet under the following 5 framework sections and headings: Review IV within
- 167 (hours) (Section 1: Timing of IV antimicrobial review); Clinical signs and symptoms (Section 2: Clinical
- signs and symptoms); Temperature, Heart rate, Blood pressure, Respiratory rate, White cell count,
- 169 C-reactive protein (Section 3: Infection markers); Gut function, Drug interactions with oral therapy,
- 170 Allergy to oral therapy (Section 4: Enteral route); and Infection exclusions (Section 5: Infection
- 171 exclusions) (Supplementary Table S2).
- 172 3.2 Study selection

173 Four hundred seventy-seven papers were identified from the literature search. Fifty-nine were non-

- 174 studies (e.g., letters, notes, conference abstracts) and therefore excluded. Akhloufi et al.'s IVOS
- 175 review in 2017<sup>21</sup> led to the timeframe of included papers to be between 2017 and 2021, excluding a

176 further 308 papers. The remaining 110 articles were screened for relevance to the research question

- 177 by title and abstract. Seventy papers were excluded due to a focus other than AMS. Forty papers
- 178 were found to be eligible for inclusion and screened by full article. A further 24 papers were
- 179 excluded as they contained no IVOS criteria or pertained to the paediatric population (n=1). Sixteen
- papers with IVOS criteria were included for review. See **Figure 1** for PRISMA flowchart.
- 181 The primary outcome of safety of antimicrobial IVOS was identified in eight of the included papers
- 182 (50%),<sup>12, 21, 23-28</sup> with remaining papers focusing on outcomes classed as additional for the purposes
- 183 of this study. All papers included measurable IVOS criteria.

#### 184 3.3 Study characteristics

- 185 Most published papers were from 2021 (n=4) and 2018 (n=4). The Netherlands had published the
- 186 most peer-reviewed articles (n=6), followed by two each from the United Kingdom and Australia,
- 187 and one each from Canada, India, Malaysia, Switzerland, Thailand and Vietnam. Eight papers
- 188 presented IVOS criteria for use in clinical practice in table format, two in flowchart format and one as
- 189 text. The remaining five articles did not state how IVOS criteria were presented. The majority (n=11)
- 190 had a Switch approach, 4 were unknown and one had a Continue approach (Table 2). Switch
- 191 approach referred to criteria being expressed in terms of 'if patient meets x criteria, consider switch
- 192 from intravenous to oral therapy', instead of the Continue approach of 'if patient does not meet x
- 193 criteria, consider continuing intravenous therapy'.
- 194 3.4 Results of individual studies
- 195 **Table 2** includes a summary of results of individual studies, including identified IVOS criteria.
- 196 3.5 Results of syntheses
- 197 Eight studies (50%) specified criteria for all 5 sections of the defined framework. Criteria with
- 198 highest, or over 50%, appearance in the literature, informed by evidence rating was collated.
- 199 Overall, 33 criteria were identified to go forward into the Delphi process (**Table 3**).

#### 200 3.5.1 Timing of intravenous antimicrobial review

- Eleven of the 16 included studies (69%) contained criteria pertaining to the timing of IV antimicrobial
   review.
- Five of the studies (30%) stated that a review should take place either within (n=3), at (n=1) or after
- 204 (n=1) the 48–72-hour window from initiation of IV antimicrobial. A clinical trial [H]<sup>9</sup> and a further two
- studies [M]<sup>26, 28</sup> defined early switch as IVOS taking place within the 48-72 hours.
- 206 Three studies (19%) stated that a review must occur within (n=1) or after (n=2) 48 hours from
- 207 initiation of IV antimicrobial. A systematic review [H] investigated early IVOS as being within 48
- 208 hours.<sup>29</sup> Three studies (19%) [M] recommended IVOS review to occur after 24 hours.<sup>27, 30, 31</sup>
- 209 3.5.2 Clinical signs and symptoms
- 210 Ten of the 16 studies (63%) included clinical signs and symptoms as a criterion for early IVOS. Nine
- studies (56%) stated that clinical signs and symptoms must be improving; one of these studies was a
- 212 (non-systematic) review article [H]. A variance in criterion wording was captured by one study that
- stated that clinical signs and symptoms must be resolved or improving for safe IVOS.<sup>21</sup>
- 214 3.5.3 Infection markers
- 215 The infection markers identified in the literature were temperature,<sup>9, 12, 21, 23, 25-28, 30-35</sup> heart rate,<sup>9, 32-34</sup>
- 216 blood pressure,<sup>12, 21, 23, 26-28, 31-35</sup> respiratory rate,<sup>9, 12, 32, 33</sup> white cell count <sup>9, 12, 24, 27, 28, 30, 32-34</sup> or
- absolute neutrophil count<sup>24, 30</sup> and C-reactive protein.<sup>32, 33</sup>
- 218 3.5.3.1 Temperature
- 219 Temperature was the most frequently mentioned infection marker, appearing in 14 of the 16 studies
- 220 (88%). The most common criterion variance was that temperature must be between the 36-38°C
- range, appearing in 6 studies (38%). Of these 6 studies, three stated that 36-38°C must have been
- sustained for the past 24 hours one of these studies was a clinical trial [H],<sup>12</sup> and one stated for the
- past 24-48 hours, also a clinical trial [H].<sup>9</sup> Six studies (38%) [M] did not state a temperature range,
- but instead suggested that it must be less than 38°C,<sup>27, 30, 31, 33, 34</sup> or less than 37.6°C.<sup>25</sup> Two studies

- 225 (13%) did not specify a temperature at all, but instead commented on the need for patient's fever to
- 226 be resolved or improving,<sup>35</sup> or patient to be afebrile.<sup>28</sup>
- 227 3.5.3.2 Heart rate
- 228 Four of the 16 studies (25%) included heart rate (HR) as an infection marker for safe IVOS. Two of
- them (12.5%) stated HR must be below 90 beats/minute the clinical trial [H] provided no
- 230 timeframe,<sup>9</sup> whilst the study [M] stated HR must have been sustained for the past 12 hours.<sup>32</sup>
- 231 3.5.3.3 Blood pressure
- 232 Eleven of the 16 studies (69%) included blood pressure (BP) as an infection marker for early IVOS.
- The most common wording for the criterion was BP needed to be stable (n=3, 19%),<sup>28, 31, 32</sup> and BP
- needed to be stable without inotropics or fluid resuscitation (n=3, 19%).<sup>21, 26, 27</sup>
- 235 3.5.3.4 Respiratory rate
- 236 Four of the 16 studies (25%) included respiratory rate (RR) as an infection marker for IVOS. Three
- studies (19%) stated RR must be below 20 breaths/minute; two of them had no associated
- timeframe,<sup>9, 33</sup> of which one was a clinical trial [H],<sup>9</sup> and the third, a study [M], stated that the
- 239 specified RR must have been sustained for the past 24 hours.<sup>32</sup>
- 240 3.5.3.5 White cell count
- 241 Nine of the 16 studies (56%) included white cell count (WCC) or absolute neutrophil count within
- criteria for early IVOS. The preferred wording was divided between WCC must be normalising (n=3,
- 243 19%)<sup>9, 27, 34</sup> and WCC must be within 4-12 x10<sup>9</sup>/L (n=3, 19%).<sup>12, 28, 33</sup> Each of these criterion wordings
- appeared in clinical trials [H].<sup>9, 12</sup>
- 245 3.5.3.6 C-reactive protein
- 246 C-reactive protein (CRP) was the least included infection marker, appearing in only 2 of the 16
- studies (13%). Both studies [M] stated that CRP must be normalising for a safe IVOS.<sup>32, 33</sup>

#### 248 3.5.4 Enteral route

- 249 Fourteen of the 16 included studies (88%) had criteria that related to the enteral route. The most
- 250 common criteria in the literature was that there must be no malabsorption, appearing in 11 of the
- 251 16 studies (69%), of which one was a clinical trial [H]<sup>9</sup> and one a review [H].<sup>35</sup>
- 252 Nine studies (56%) stated that the gut must be functioning and 5 studies (31%) stated the patient
- 253 must not be vomiting.
- 254 3.5.5 Infection exclusions
- 255 This section included both general information (e.g., infections requiring prolonged IV therapy, deep-
- seated infections) as well as specifically mentioned infections. The infections with highest counts in
- the literature were endocarditis (n=12, 75%) including in two clinical trials [H]<sup>9, 12</sup> and one review<sup>35</sup>
- and meningitis (n=8, 50%). Infections with lowest appearance in the literature included mediastinitis
- 259 (n=4, 25%) and bone and joint infections (n=2, 12.5%).

### 260 4 Discussion

261 Early IVOS has numerous advantages compared to continuing intravenous therapy in patients that 262 may be eligible for oral administration. The risk of cannula-related infections and thrombophlebitis 263 would reduce, as would the costs of equipment and staff time. Patient comfort and mobility would 264 be promoted, and the absence of intravenous antimicrobial infusions or injections could result in earlier patient discharge from hospital.<sup>36</sup> Analysis of individualised hospital IVOS policies showcased 265 266 the variety of IVOS criteria in clinical use. The standardisation of healthcare practice benefits patient safety and outcomes, however it must be evidence-based.<sup>37</sup> Through this rapid review, the literature 267 268 was systematically searched and 33 IVOS criteria were identified as part of a 5-section framework.

269 4.1 Criteria sections

270 4.1.1 Timing of intravenous antimicrobial review

271 The most common timing stated in the literature for IVOS review from initiation of antimicrobial

intravenous therapy was 48-72 hours, specifically within the 48–72-hour window. Prior guidance

273	outlines the need to review patients' clinical diagnosis and ongoing need for antibiotics at 48-72
274	hours. <sup>38, 39</sup> In the UK national Start Smart – Then Focus AMS Toolkit, <sup>38</sup> switching antibiotics from
275	intravenous to oral is one of five recommended choices, alongside stopping antibiotics, changing to
276	a narrower or broader spectrum antibiotic, continuing antibiotic treatment stating time of next
277	review or considering Outpatient Parenteral Antibiotic Therapy. Studies have since questioned
278	whether an earlier review, such as review within 48 hours of intravenous initiation, is warranted. <sup>29, 40</sup>
279	Van den Broek et al. commented that theoretical reasons for an early switch (even within 24 hours)
280	exist; for example, if patient has an intact gastrointestinal tract and the oral antibiotic option has
281	adequate bioavailability (generally data obtained from studies carried out in healthy and/or critically
282	ill patients). However, improved knowledge on antimicrobial bioavailability in the acute stage of
283	infectious illness, when the patient may be febrile and drug pharmacokinetics more unfamiliar,
284	would further strengthen the case for earlier IVOS. <sup>29</sup>
285	4.1.2 Clinical signs and symptoms
286	Signs as objective manifestations of infectious disease, and symptoms as subjective manifestations, <sup>41</sup>
287	underline the importance of noting improvement, or deterioration, in both the observed response to
288	infection and its management as well as the self-reported accounts of the patient. This rapid review
289	showcases evidence to suggest that the improvement of a patient's signs and symptoms is an
290	important criterion to include for safe IVOS. <sup>21, 24-27</sup>
291	4.1.3 Infection markers
292	Temperature was the predominant infection marker criterion across all studies, with higher evidence
293	for stating a temperature range compared to stating that temperature must be below a certain
294	figure. Infection can elicit thermoregulation in the host, increasing body temperature
295	(fever/hyperthermia) or decreasing it (hypothermia) as in the case of sepsis, <sup>42</sup> thus corroborating the
296	importance of including a temperature range in IVOS criteria.
207	Despite temperature being a vital marker of infection, normathermia, categorized as 26.1.20°C, has

- 297 Despite temperature being a vital marker of infection, normothermia, categorised as 36.1-38°C, has
- 298 been associated with infection and higher patient mortality than hyperthermia.<sup>43</sup> Normothermia

299 therefore does not exclude the need for antibiotics; and if antibiotics are given, normothermia 300 would not necessarily mean that a switch from intravenous to oral therapy should be made. Other infection markers, to include physiological and inflammatory parameters,<sup>43</sup> must be considered to 301 302 ensure any IVOS decision is safe. 303 The National Early Warning Score (NEWS) developed by the UK Royal College of Physicians is a 304 recognised clinical assessment tool for use in acute hospital and ambulance settings. It was first 305 published in 2012 with a second version, NEWS2, released in 2017. The tool 'improves the detection 306 and response to clinical deterioration in adult patients and is a key element of patient safety and improving patient outcomes'.<sup>13,44</sup> NEWS2 aggregates individual scores from the following 307 308 physiological parameters: respiration rate, oxygen saturation, systolic blood pressure, pulse rate, 309 level of consciousness or new confusion, and temperature. Certain parameters overlap with the 310 IVOS criteria found in the literature, notably temperature, but also respiration/respiratory rate and 311 blood pressure. The marker named heart rate in this rapid review is specified as pulse rate in 312 NEWS2. 313 For each marker of HR, BP and RR, the literature showcased a variety of nuances in criteria wording. 314 Some criteria, but not all, specify marker values with or without a particular timeframe for which the 315 specified infection marker must be sustained for; e.g., HR below 90 beats/min for the past 12 hours. 316 The benefit of the NEWS2 score is that ranges, not merely single values, are used to assess clinical 317 deterioration. Additionally, it is a tool endorsed for use in patients with acute infection or at risk of infection and widely implemented across UK NHS hospitals.<sup>13</sup> Presenting separate criteria for HR, BP 318 and RR is one way to achieve safe IVOS,<sup>12, 21, 23, 26-28</sup> however presenting them combined into a 319 320 NEWS2 scoring criterion would offer an alternative evidence-based way to achieve safe IVOS. 321 Other countries have also adopted Early Warning Scores (EWS) to identify patients at risk of 322 deterioration, especially from infection, thus IVOS criteria in other countries could consider EWS as a 323 criterion. In Canada, for example, the Hamilton Early Warning Score of similar prognostic accuracy to

324 NEWS2 is used.<sup>45</sup> In the United States of America, a variety of tools exist with the NEWS tool

325 considered most accurate to identify patients at high risk of mortality.<sup>46</sup>

#### 326 4.1.4 Enteral route

- 327 This section of the framework is concerned with maximising enteral antibiotic absorption from the
- 328 gastrointestinal tract (GIT), and hence maximising antibiotic bioavailability and therapeutic action.
- 329 Antibiotic administration via the intravenous route achieves 100% bioavailability.<sup>36</sup> Some antibiotics
- are known to have good oral bioavailability, for example clindamycin, doxycycline, linezolid and
- 331 metronidazole have over 90% oral bioavailability.<sup>36, 47</sup>
- 332 The literature outlines numerous criteria to ensure a switch to oral administration, or indeed to
- enteral administration to include use of enteral tubes, achieves as close to 100% bioavailability as
- 334 practicable. The criteria centre on patient characteristics, predominantly in relation to their GIT
- function e.g., no malabsorption present, but also in relation to their level of alertness e.g., patient is
- not unconscious. The latter resonates with one of the physiological scores included in the NEWS2
- 337 (level of consciousness or new confusion scoring),<sup>13</sup> further promoting inclusion of EWS as a
- 338 combination criterion for safe IVOS.
- 339 The literature includes no mention of antibiotic pharmacological properties such as antibiotic
- bioavailability, nor the need to review drug interactions between oral antibiotic options and any
- 341 other medication the patient may be taking or to check for allergies. It is worth noting that these
- 342 criteria do appear in the sample of acute hospital IVOS policies used to inform the framework
- 343 analysis (Supplementary Table S2).
- 344 4.1.5 Infection exclusions

345 Over the years, randomised controlled trials have been undertaken comparing treatment arms of

- 346 prolonged intravenous antibiotic courses and shorter courses. The research has demonstrated equal
- 347 outcomes between treatment arms for infections such as community-acquired pneumonia and
- 348 neutropenic fever.<sup>48</sup> These results have enabled change in clinical practice and advancement in AMS.

349	However, not all infections have the evidence to make them eligible for early IVOS. This section of
350	the framework provides a caveat around certain infections when making early IVOS decisions.
351	Endocarditis was the infection exclusion with highest appearance in the literature. The POET trial
352	enrolled patients with left-sided endocarditis and compared full course intravenous therapy versus
353	oral switch after a minimum of 10 days intravenous therapy. IVOS was found to be noninferior in
354	terms of treatment failure at one year compared to full intravenous therapy. <sup>49</sup> However, the timing
355	of IVOS (after at least 10 days of intravenous therapy) was much later than the timing for IVOS
356	proposed in the included literature for this rapid review. Considering the current available evidence,
357	endocarditis may remain as an infection exclusion within IVOS criteria.
358	Bone and joint infections appeared only twice in the literature, in papers published in 2018 <sup>34</sup> and
359	2019. <sup>30</sup> Around that time, the OVIVA trial investigated early IVOS for bone and joint infections and
360	concluded that oral antibiotic treatment was noninferior to intravenous treatment. Trial IVOS
361	decisions were led by specialist teams, <sup>50</sup> so it remains to be said that in the standardisation process
362	of IVOS criteria, which also serves to equip non-specialist teams, professional judgment regarding
363	when to refer patients for specialist input remains important in IVOS decision-making.

#### 364 4.2 Strengths and limitations

A strength of this study includes a systematic literature search being undertaken to capture papers relevant to IVOS AMS strategy. Papers were not limited by country or region, thus the criteria identified can serve as a starting point for any institution globally. Two researchers (EH, DAO) were involved in reviewing themes and included papers, with a separate researcher (MM) undertaking a

- 369 second assessment of a random sample of papers.
- 370 A limitation is that non-English papers were excluded, potentially discounting research on IVOS
- 371 criteria conducted in non-English speaking nations. During the study period, the authors were not
- aware of a published validated rapid review reporting protocol.<sup>51</sup> However, the WHO and Cochrane
- approaches to rapid reviews were taken into consideration and the authors followed through the
- 374 PRISMA reporting guidelines.

# 375 5 Conclusion

- 376 The benefits of early IVOS include reduced risk of healthcare-associated and catheter-related
- 377 infections, reduced costs, staff workload and hospital length of stay, and increased patient mobility
- and comfort. Individual hospital polices contain variable IVOS criteria with an unknown evidence-
- base. This rapid review has identified and collated 33 evidence-based IVOS criteria from the
- 380 literature and presented them within 5 distinct and comprehensive sections.
- 381 Further research is required to achieve a national consensus on IVOS criteria from healthcare
- 382 professionals providing the care for hospitalised adult patients and making the decisions regarding
- infection management. In the acute hospital setting, operationalisation of IVOS criteria as a tool to
- 384 promote best practice needs to be explored and must take into consideration the roles and
- 385 strengths that a multidisciplinary team brings to AMS.

# 386 6 Author contributions

- 387 Conceptualisation: DAO, EH. Methodology: EH undertook framework analysis, literature review and
- 388 drafted paper, CD contributed to literature searches, MM undertook the random second assessment
- of articles, DAO validated aspects of methodology and supervised the review. All authors reviewed
- 390 and approved final version.

### 391 7 Funding

- 392 This research was funded by the UK Health Security Agency. The views expressed in this publication
- are those of the author(s) and not necessarily those of the UK Health Security Agency.
- 394 8 Declarations
- 395 None to declare.
- 396 9 Ethics approval
- 397 This study does not involve human participants.

### 398 10 Data availability statement

All data relevant to the study are included in the article or uploaded as supplemental information.

Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in

# 400 11 References

401

1.

402		2019: a systematic analysis. <i>Lancet</i> , 2022. 399(10325): p. 629-655.
403	2.	O'Neill J. Tackling drug-resistant infectios globally: final report and recommendations. 2016,
404		[Date accessed: August 2022]: https://apo.org.au/sites/default/files/resource-files/2016-
405		05/apo-nid63983.pdf
406	3.	European Centre for Disease Prevention and Control. Summary of the latest data on
407		antibiotic consumption in the European Union. 2017, [Date accessed: August 2022]:
408		https://www.ecdc.europa.eu/sites/default/files/documents/Final_2017_EAAD_ESAC-
409		Net Summary-edited%20-%20FINALwith%20erratum.pdf
410	4.	UK Health Security Agency. English surveillance programme for antimicrobial utilisation and
411		resistance (ESPAUR) report. 2021, [Date accessed: August 2022]:
412		https://www.gov.uk/government/publications/english-surveillance-programme-
413		antimicrobial-utilisation-and-resistance-espaur-report.
414	5.	Dyar OJ, Huttner B, Schouten J, et al. What is antimicrobial stewardship? Clin Microbiol
415		Infect, 2017. 23(11): p. 793-798.
416	6.	Viasus D, Vecino-Moreno M, De La Hoz JM, et al. Antibiotic stewardship in community-
417		acquired pneumonia. Expert Rev Anti Infect Ther, 2017. 15(4): p. 351-359.
418	7.	Ashiru-Oredope D, Kerr F, Hughes S, et al. Assessing the impact of COVID-19 on antimicrobial
419		stewardship activities/programs in the United Kingdom. Antibiotics, 2021. 10(2): p. 110.
420	8.	Goff DA, Bauer KA, Reed EE, et al. Is the "low-hanging fruit" worth picking for antimicrobial
421		stewardship programs? Clin Infect Dis, 2012. 55(4): p. 587-592.
422	9.	Nguyen AD, Mai-Phan TA, Tran MH, et al. The effect of early switching from intravenous to
423		oral antibiotic therapy: a randomized controlled trial. J Pharm Pharmacogn Res, 2021. 9(5):
424		p. 695-703.
425	10.	Schuts EC, Hulscher M, Mouton JW, et al. Current evidence on hospital antimicrobial
426		stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis, 2016.
427		16(7): p. 847-856.
428	11.	Tennison I, Roschnik S, Ashby B <i>, et al.</i> Health care's response to climate change: a carbon
429		footprint assessment of the NHS in England. The Lancet Planetary Health, 2021. 5(2): p. e84-
430		e92.
431	12.	Wongkamhla T, Khan-Asa B, Tongsai S <i>, et al</i> . Infectious Disease Team Review Using
432		Antibiotic Switch and Discharge Criteria Shortens the Duration of Intravenous Antibiotic: A
433		Single-Center Cluster-Randomized Controlled Trial in Thailand. Open Forum Infect Dis, 2020.
434		7(12): p. ofaa539.
435	13.	Royal College of Physicians. National Early Warning Score (NEWS) 2: Standardising the
436		assessment of acute-illness severity in the NHS. 2017, [Date accessed: August 2022]:
437		https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2.
438	14.	ACOG. Clinical guidelines and standardization of practice to improve outcomes. Committee
439		opinion no. 629. Obstet Gynecol, 2015. 125(4): p. 1027-1029.
440	15.	Stone J. Defining standardization and personalized care, Medical GPS, Editor. 2020, [Date
441		accessed: August 2022]: <a href="https://blog.medicalgps.com/defining-standardization-and-">https://blog.medicalgps.com/defining-standardization-and-</a>
442		personalized-care/.
443	16.	Tricco AC, Langlois E, Straus SE <i>, et al.,</i> Rapid reviews to strengthen health policy and
444		systems: a practical guide. 2017: World Health Organization.
445	17.	Garritty C, Gartlehner G, Nussbaumer-Streit B, et al. Cochrane Rapid Reviews Methods
446		Group offers evidence-informed guidance to conduct rapid reviews. Journal of clinical
447		epidemiology, 2021. 130: p. 13-22.
448	18.	Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline
449		for reporting systematic reviews. Syst Rev, 2021. 10(1): p. 1-11.

450	19.	Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated
451		guidance and exemplars for reporting systematic reviews. BMJ, 2021. 372.
452	20.	Harvey E and Ashiru-Oredope D. Criteria to achieve safe and effective antimicrobial
453		intravenous to oral switch in hospitalised adults: a rapid review. PROSPERO, 2022.
454		CRD42022320343.
455	21.	Akhloufi H, Hulscher M, Melles DC, et al. Development of operationalized intravenous to oral
456		antibiotic switch criteria. <i>J Antimicrob Chemother</i> , 2017. 72(2): p. 543-546.
457	22.	Haby MM, Chapman E, Clark R, <i>et al.</i> What are the best methodologies for rapid reviews of
458		the research evidence for evidence-informed decision making in health policy and practice: a
459		rapid review. <i>Health Syst Policy Res</i> , 2016. 14(1): p. 1-12.
460	23.	Akhloufi, H, M Hulscher, CP Van Der Hoeven <i>, et al.</i> A clinical decision support system
461		algorithm for intravenous to oral antibiotic switch therapy: Validity, clinical relevance and
462		usefulness in a three-step evaluation study. Journal of Antimicrobial Chemotherapy, 2018.
463		73(8): p. 2201-2206.
464	24.	Berrevoets, MAH, JHLW Pot, AE Houterman, et al. An electronic trigger tool to optimise
465		intravenous to oral antibiotic switch: A controlled, interrupted time series study.
466		Antimicrobial Resistance and Infection Control, 2017. 6(1) (no pagination).
467	25.	Kan T, Kwan D, Chan T, et al. Implementation of a Clinical Decision Support Tool to Improve
468		Antibiotic IV-to-Oral Conversion Rates at a Community Academic Hospital. Can J Hosp
469		<i>Pharm</i> , 2019. 72(6): p. 455-461.
470	26.	Khumra S, Mahony AA, Bergen PJ <i>, et al.</i> Evaluation of intravenous to oral antimicrobial
471	20.	switch at a hospital with a tightly regulated antimicrobial stewardship program. Br J Clin
472		<i>Pharmacol</i> , 2021. 87(8): p. 3354-3358.
473	27.	Tejaswini YS, Challa SR, Nalla KS, <i>et al.</i> Practice of intravenous to oral conversion of
474	27.	antibiotics and its influence on length of stay at a tertiary care hospital: A prospective study.
475		J Clin Diagn Res, 2018. 12(3): p. FC01-FC04.
476	28.	Van Den Bosch CMA, Hulscher MEJL, Akkermans RP, et al. Appropriate antibiotic use reduces
477	20.	length of hospital stay. J Antimicrob Chemother, 2017. 72(3): p. 923-932.
478	29.	van den Broek AK, Prins JM, Visser CE, <i>et al.</i> Systematic review: the bioavailability of orally
479	25.	administered antibiotics during the initial phase of a systemic infection in non-ICU patients.
479		BMC Infect Dis, 2021. 21(1) (no pagination).
480 481	30.	Gurtler N, Erba A, Giehl C, <i>et al.</i> Appropriateness of antimicrobial prescribing in a Swiss
481	50.	tertiary care hospital: a repeated point prevalence survey. Swiss Med Wkly, 2019. 149: p.
		w20135.
483	21	
484	31.	Mouwen AMA, Dijkstra JA, Jong E, et al. Early switching of antibiotic therapy from
485		intravenous to oral using a combination of education, pocket-sized cards and switch advice:
486		A practical intervention resulting in reduced length of hospital stay. Int J Antimicrob Agents,
487	22	2020. 55(1): p. 105769.
488	32.	Dutey-Magni PF, Gill MJ, McNulty D, et al. Feasibility study of hospital antimicrobial
489		stewardship analytics using electronic health records. JAC Antimicrob Resist, 2021. 3(1) (no
490		pagination).
491	33.	Powell N, McGraw-Allen K, Menzies A, et al. Identifying antibiotic stewardship interventions
492		to meet the NHS England CQUIN: An evaluation of antibiotic prescribing against published
493		evidence-based antibiotic audit tools. <i>J R Coll Physicians Lond</i> , 2018. 18(4): p. 276-281.
494	34.	Sze WT and Kong MC. Impact of printed antimicrobial stewardship recommendations on
495		early intravenous to oral antibiotics switch practice in district hospitals. <i>Pharm Pract</i> , 2018.
496	<i>c</i> =	16(2): p. 855.
497	35.	McCarthy K and Avent M. Oral or intravenous antibiotics? <i>Aust Prescr</i> , 2020. 43(2): p. 45-48.
498	36.	Cyriac JM and James E. Switch over from intravenous to oral therapy: a concise overview. J
499		Pharmacol Pharmacother, 2014. 5(2): p. 83-87.

500	37.	World Medical Association. WMA resolution on standardiation in medical practice and
501		patient safety, in <i>Current Policies,</i> , Policy, Editor. 2022, <i>[Date accessed: August 2022]</i> :
502		https://www.wma.net/policies-post/wma-resolution-on-standardisation-in-medical-
503		practice-and-patient-safety/.
504	38.	Public Health England. Start Smart – Then Focus: Antimicrobial stewardship toolkit for
505		English hospitals. 2015, [Date accessed: August 2022]:
506		https://www.gov.uk/government/publications/antimicrobial-stewardship-start-smart-then-
507		<u>focus</u> .
508	39.	Nathwani D, Lawson W, Dryden M, et al. Implementing criteria-based early switch/early
509		discharge programmes: A European perspective. Clin Microbiol Infect, 2015. 21(Supplement
510		2): p. S47-S55.
511	40.	Cunha CB. Antibiotic stewardship program perspective: Oral antibiotic therapy for common
512		infectious diseases. <i>Med Clin</i> , 2018. 102(5): p. 947-954.
513	41.	King LS. Signs and symptoms. JAMA, 1968. 206(5): p. 1063-1065.
514	42.	Schieber AMP and Ayres JS. Thermoregulation as a disease tolerance defense strategy.
515		Pathog Dis, 2016. 74(9).
516	43.	Schuttevaer R, Brink A, Alsma J, et al. The association of body temperature with antibiotic
517		therapy and mortality in patients attending the emergency department with suspected
518		infection. Eur J Emerg Med, 2021. 28(6): p. 440.
519	44.	NHS England. National Early Warning Score (NEWS). 2022, [Date accessed: August 2022]:
520		https://www.england.nhs.uk/ourwork/clinical-policy/sepsis/nationalearlywarningscore/.
521	45.	Fernando SM, Fox-Robichaud AE, Rochwerg B <i>, et al.</i> Prognostic accuracy of the Hamilton
522		Early Warning Score (HEWS) and the National Early Warning Score 2 (NEWS2) among
523		hospitalized patients assessed by a rapid response team. <i>Critical Care,</i> 2019. 23(1): p. 1-8.
524	46.	Liu VX, Lu Y, Carey KA <i>, et al</i> . Comparison of early warning scoring systems for hospitalized
525		patients with and without infection at risk for in-hospital mortality and transfer to the
526		intensive care unit. JAMA network open, 2020. 3(5): p. e205191-e205191.
527	47.	Quinn NJ, Sebaaly JC, Patel BA, et al. Effectiveness of oral antibiotics for definitive therapy of
528		non-Staphylococcal Gram-positive bacterial bloodstream infections. Therapeutic Advances in
529		Infectious Disease, 2019. 6: p. 2049936119863013.
530	48.	Wald-Dickler N and Spellberg B. Short-course antibiotic therapy—replacing constantine units
531		with "shorter is better". 2019, Oxford University Press US. p. 1476-1479.
532	49.	Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of
533		endocarditis. <i>N Engl J Med</i> , 2019. 380(5): p. 415-424.
534	50.	Li H-K, Rombach I, Zambellas R, et al. Oral versus intravenous antibiotics for bone and joint
535		infection. N Engl J Med, 2019. 380(5): p. 425-436.
536	51.	Stevens A, Garritty C, Hersi M, et al. Developing PRISMA-RR, a reporting guideline for rapid
537		reviews of primary studies (Protocol). equator network, 2018.
538		
550		

#### Table 1. OVID Embase and OVID Medline search strategies


#### **OVID Embase**

- 1. exp \*antiinfective agent/
- 2. exp \*anti-infective therapy/
- 3. exp \*antimicrobial therapy/
- 4. antimicrobial stewardship.tw.
- 5. 1 or 2 or 3 or 4
- 6. ((IV or intravenous or early or antibiotic or oral) adj3 switch\*).tw.
- 7. IVOS\*.tw.
- 8. 6 or 7
- 9. 5 and 8
- 10 limit 9 to (human and english language)

#### **OVID Medline**

- 1. Anti-Infective Agents/
- 2. Antimicrobial Stewardship/
- 3. 1 or 2
- 4. ((IV or intravenous or early or antibiotic or oral) adj3 switch\*).tw.
- 5. IVOS\*.tw.
- 6. 4 or 5
- 7. 3 and 6





Article	Outcome sought	Evidence rating	Layout	Approach	Timing of IV antimicrobial review (h)	Clinical signs and symptoms	Infection markers	Enteral route	Infection exclusions
Akhlou fi H et al., 2017 <sup>1</sup>	Safety of IVOS	[M]	Table	Switch	After 48-72	Resolved or improving	Temperature 36-38 °C, BP stable without inotropics or fluid resuscitation	Functioning gut; no malabsorption, short bowel syndrome, severe gastroparesis, ileus, continuous nasogastric suction, vomiting; patient is cooperative	Infections requiring high concentration; severe sepsis, necrotising fasciitis, bacteraemia, endovascular infection, CNS infection
Akhlou fi et al., 2018 <sup>2</sup>	Safety of IVOS	[M]	Table	Switch	-	-	Temperature 36-38 °C (past 24h), BP >90 mmHg	-	-
Berrev oets et al., 2017 <sup>3</sup>	Safety of IVOS	[M]	Table	Switch	At 48-72	Improving	ANC >0.5 x10 <sup>9</sup> /L	Functioning gut; no malabsorption, short bowel syndrome, vomiting, nausea; patient tolerates oral route	Infections requiring prolonged IV therapy; necrotising fasciitis, bacteraemia, endocarditis, meningitis, neutropenia, abscess, mediastinitis, infection of foreign bodies, cystic fibrosis, empyema

Table 2. Summary of results of individual studies

Dutey- Magni PF et al., 2021 <sup>4</sup>	Improved AMS practice	[M]	Text	Switch	-	Improving	Temperature 36-38 °C (past 24h), HR <90 beats/min (past 12h), BP stable (past 24h), RR <20 breaths/min (past 24h), WCC 4-12 x10 <sup>9</sup> /L or normalising, CRP normalising	Functioning gut; no malabsorption; patient tolerates oral/enteral feeding	Deep-seated, high- risk infections and infections requiring high concentration; necrotising soft tissue, bacteraemia, endocarditis, meningitis, neutropenia, abscess, mediastinitis, foreign body infection, cystic fibrosis, bronchiectasis, osteomyelitis, septic arthritis, pneumonia
Gurtle r N et al., 2019 <sup>5</sup>	Improved AMS practice	[M]	Unknown	Switch	After 24	Improving	Temperature <38 °C, ANC >0.5 x10 <sup>9</sup> /L	Functioning gut	Endocarditis, abscess, bone/joint infection
Kan T et al., 2019 <sup>6</sup>	Safety of IVOS Improved AMS practice	[M]	Table	Switch	After 48	Improving	Temperature <37.6 °C (past 24h)	Functioning gut; not nil by mouth; patient tolerates oral route	Bacteraemia, endocarditis, meningitis, neutropenia
Khumr a S et al., 2021 <sup>7</sup>	Safety of IVOS Improved AMS practice	[M]	Flowchart	Continue	Within 48-72	Improving	Temperature 36-38 °C, BP stable without inotropics or fluid resuscitation	No malabsorption, short bowel syndrome, ileus, vomiting, severe diarrhoea, not nil by mouth; patient tolerates	Deep-seated infections; necrotising soft tissue, bacteraemia, endocarditis, meningitis, neutropenia, abscess, implant of prosthesis

								oral/enteral feeding	infection, empyema, osteomyelitis, septic arthritis
McCar thy K & Avent M, 2020 <sup>8</sup>	Improved AMS practice	[H]	Table	Switch	-	Improving	Fever resolved or improving, no unexplained haemodynamic instability	No malabsorption; patient tolerates oral route	Infections requiring high concentration and prolonged IV therapy; endocarditis, meningitis
Mouw en AMA et al., 2020 <sup>9</sup>	Improved AMS practice Reduced hospital length of stay	[M]	Flowchart	Switch	After 24	Improving	Temperature <38 °C (past 24h), BP stable (past 24h)	No malabsorption, vomiting, diarrhoea; patient tolerates oral route	-
Nguye n AD et al., 2021 <sup>10</sup>	Effective- ness of IVOS Reduced hospital length of stay Reduced costs	[H]	Unknown	Unknown	Within 48-72	-	Temperature 36-38 °C (past 24-48h), HR <90 beats/min, RR <20 breaths/min, WCC normalising	No malabsorption, ileus, severe diarrhoea, gastrectomy, dysphagia; patient tolerates oral route, not unconscious	Septic shock, cellulitis, bacteraemia, endocarditis, meningitis, immunodeficiency, prosthetic material infection, osteomyelitis, pneumonia, cirrhosis
Powell N et al., 2018 <sup>11</sup>	Improved AMS practice	[M]	Table	Switch	-	-	Temperature <38 °C (past 24h), HR <100 beats/min (past 12h), BP >100	Functioning gut; no malabsorption; patient tolerates oral route	Deep-seated infections; bacteraemia, endocarditis, meningitis,

							mmHg, RR <20 breaths/min, WCC 4-12 x10 <sup>9</sup> /L, CRP normalising		neutropenia, abscess, mediastinitis, prosthetic device or foreign body infection, cystic fibrosis, bronchiectasis, empyema, osteomyelitis, septic arthritis, pneumonia
Sze WT & Kong MC, 2018 <sup>12</sup>	Improved AMS practice Reduced hospital length of stay Reduced costs	[M]	Unknown	Unknown	After 48	Improving	Temperature <38 °C (past 24h), HR <100 beats/min, BP >90 mmHg, WCC normalising	Functioning gut; no malabsorption, vomiting, severe diarrhoea, swallowing disorder, active bleeding, not nil by mouth; patient tolerates oral route, not unconscious	Infections requiring prolonged IV therapy; sepsis, bacteraemia, endocarditis, meningitis, immunodeficiency, abscess, cystic fibrosis, empyema, bone/joint infection, orbital cellulitis, endophthalmitis, melioidosis
Tejasw ini YS et al., 2018 <sup>13</sup>	Safety of IVOS Improved AMS practice Reduced hospital length of stay	[M]	Unknown	Unknown	After 24	Improving	Temperature <38 °C (past 24h), BP stable without inotropics or fluid resuscitation, WCC normalising	No malabsorption, active bleeding; patient tolerates oral/enteral feeding	Infections requiring prolonged IV therapy; sepsis, bacteraemia, endocarditis, CNS infection, immunodeficiency, osteomyelitis, septic arthritis, fungemia, endophthalmitis, orbital cellulitis

	Reduced costs							
van den Bosch CMA et al., 2017 <sup>14</sup>	Safety of IVOS Reduced hospital length of stay Reduced costs	[M]	Table	Switch	Within 48-72 -	Afebrile, BP stable, WCC 4- 12 x10 <sup>9</sup> /L	Functioning gut; no malabsorption; patient tolerates oral route	Soft tissue infections, bacteraemia, endocarditis, meningitis, neutropenia, abscess, mediastinitis, foreign body infection, cystic fibrosis, empyema, osteomyelitis, arthritis, Legionella pneumonia
van den Broek AK et al., 2021 <sup>15</sup>	Improved AMS practice	[H]	Unknown	Unknown	Within 48 -	-	-	-
Wong kamhl a T et al., 2020 <sup>16</sup>	Safety of IVOS Reduced hospital length of stay	[H]	Table	Switch		Temperature 36-38 °C (past 24h), BP >100 mmHg, RR <22 breaths/min, WCC 4-12 x10 <sup>9</sup> /L	Functioning gut; patient tolerates oral route	Sepsis, endocarditis, CNS infection, neutropenia

# Table 2 References

- 1. Akhloufi H, Hulscher M, Melles DC, *et al.* Development of operationalized intravenous to oral antibiotic switch criteria. *J Antimicrob Chemother*, 2017. 72(2): p. 543-546.
- Akhloufi, H, M Hulscher, CP Van Der Hoeven, et al. A clinical decision support system algorithm for intravenous to oral antibiotic switch therapy: Validity, clinical relevance and usefulness in a three-step evaluation study. *Journal of Antimicrobial Chemotherapy*, 2018. 73(8): p. 2201-2206.
- 3. Berrevoets, MAH, JHLW Pot, AE Houterman, *et al.* An electronic trigger tool to optimise intravenous to oral antibiotic switch: A controlled, interrupted time series study. *Antimicrobial Resistance and Infection Control*, 2017. 6(1) (no pagination).
- 4. Dutey-Magni PF, Gill MJ, McNulty D, *et al.* Feasibility study of hospital antimicrobial stewardship analytics using electronic health records. *JAC Antimicrob Resist*, 2021. 3(1) (no pagination).
- 5. Gurtler N, Erba A, Giehl C, *et al.* Appropriateness of antimicrobial prescribing in a Swiss tertiary care hospital: a repeated point prevalence survey. *Swiss Med Wkly*, 2019. 149: p. w20135.
- 6. Kan T, Kwan D, Chan T, *et al.* Implementation of a Clinical Decision Support Tool to Improve Antibiotic IV-to-Oral Conversion Rates at a Community Academic Hospital. *Can J Hosp Pharm*, 2019. 72(6): p. 455-461.
- 7. Khumra S, Mahony AA, Bergen PJ, *et al.* Evaluation of intravenous to oral antimicrobial switch at a hospital with a tightly regulated antimicrobial stewardship program. *Br J Clin Pharmacol*, 2021. 87(8): p. 3354-3358.
- 8. McCarthy K and Avent M. Oral or intravenous antibiotics? *Aust Prescr*, 2020. 43(2): p. 45-48.
- Mouwen AMA, Dijkstra JA, Jong E, et al. Early switching of antibiotic therapy from intravenous to oral using a combination of education, pocket-sized cards and switch advice: A practical intervention resulting in reduced length of hospital stay. Int J Antimicrob Agents, 2020. 55(1): p. 105769.
- 10. Nguyen AD, Mai-Phan TA, Tran MH, *et al*. The effect of early switching from intravenous to oral antibiotic therapy: a randomized controlled trial. *J Pharm Pharmacogn Res*, 2021. 9(5): p. 695-703.
- 11. Powell N, McGraw-Allen K, Menzies A, *et al.* Identifying antibiotic stewardship interventions to meet the NHS England CQUIN: An evaluation of antibiotic prescribing against published evidence-based antibiotic audit tools. *J R Coll Physicians Lond*, 2018. 18(4): p. 276-281.
- 12. Sze WT and Kong MC. Impact of printed antimicrobial stewardship recommendations on early intravenous to oral antibiotics switch practice in district hospitals. *Pharm Pract*, 2018. 16(2): p. 855.
- 13. Tejaswini YS, Challa SR, Nalla KS, *et al.* Practice of intravenous to oral conversion of antibiotics and its influence on length of stay at a tertiary care hospital: A prospective study. *J Clin Diagn Res*, 2018. 12(3): p. FC01-FC04.
- 14. Van Den Bosch CMA, Hulscher MEJL, Akkermans RP, *et al.* Appropriate antibiotic use reduces length of hospital stay. *J Antimicrob Chemother*, 2017. 72(3): p. 923-932.
- 15. van den Broek AK, Prins JM, Visser CE, *et al.* Systematic review: the bioavailability of orally administered antibiotics during the initial phase of a systemic infection in non-ICU patients. *BMC Infect Dis*, 2021. 21(1) (no pagination).
- Wongkamhla T, Khan-Asa B, Tongsai S, et al. Infectious Disease Team Review Using Antibiotic Switch and Discharge Criteria Shortens the Duration of Intravenous Antibiotic: A Single-Center Cluster-Randomized Controlled Trial in Thailand. Open Forum Infect Dis, 2020. 7(12): p. ofaa539.

#### Criteria Number of papers **Evidence rating** n, (%) 1. Timing of IV antimicrobial review a. Review antimicrobial within 48 hours 1 (6) [H] b. Review antimicrobial within **48-72 hours** [M] x2, [H] 3 (19) 2. Clinical signs and symptoms a. Clinical signs and symptoms should be 9 (56) [M] x8, [H] improving 3. Infection markers a. Temperature should be between 36-38°C 2 (13) [M] x2 b. Temperature should be between 36-38 °C [M] x2, [H] 3 (19) past 24 hours c. Heart rate should be below 90 beats per 1 (6) [H] minute d. Heart rate should be below 90 beats per 1 (6) [M] minute for past 12 hours e. Blood pressure should be stable 1 (6) [M] f. Blood pressure stable for past 24 hours [M] x2 2 (13) g. Respiratory rate should be below 20 2 (13) [M], [H] breaths per minute h. Respiratory rate should be below 20 1 (6) [M] breaths per minute for past 24 hours i. White cell count should be normalising 3 (19) [M] x2, [H] j. White cell count should be between 4 and 3 (19) [M] x2, [H] 12 x10^9/L k. White cell count should be between 4 and 1 (6) [M] 12 x10<sup>9</sup>/L or normalising I. C-reactive protein should be normalising 2 (13) [M] x2 4. Enteral route a. Gastrointestinal tract must be functional 9 (57) [M] x8, H b. Patient can tolerate/ swallow oral option 9 (57) [M] x6, [H]x3 c. No evidence of malabsorption 11 (69) [M] x9, [H] x2 d. No vomiting 5 (31) [M] x5 5. Infection exclusions a. Deep-seated infections 3 (19) [M] x3 b. Infections requiring high tissue 3 (19) [M] x2, [H] concentration c. Infections requiring prolonged IV therapy 4 (25) [M] x3, [H]

#### Table 3. Criteria from rapid review (n=33) to go forward into Delphi process

d. Critical infection with high risk of mortality	1 (6)	[M]
e. Endocarditis	12 (75)	[M] x9, [H] x3
f. Meningitis	9 (56)	[M] x7, [H] x2
g. Bacteraemia, including Staph. aureus	9 (56)	[M] x9
h. Immunocompromised	3 (19)	
i. Abscess	7 (44)	[M] x7
j. Severe or necrotising soft tissue infections	5 (31)	[M] x5
k. Infections of foreign bodies	6 (38)	[M] x5, [H]
l. Osteomyelitis	6 (38)	[M] x5, [H]
m. Septic arthritis	5 (31)	[M] x5
n. Empyema	5 (31)	[M] x5